pulmonary arterial hypertension

News

NICE backs stomach cancer, PAH drugs for NHS use

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

United's PAH drug clears phase 3 trial, setting up filings

United Therapeutics will file ralinepag as a treatment for pulmonary arterial hypertension later this year, but can it compete in a crowded market?

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

News

Keros pulls study of Winrevair rival after safety signal

Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair.

News

Safety fear halts Keros PAH trial dosing, hitting its shares

An unexpected side effect has led Keros to halt dosing in two arms of its phase 2 trial of pulmonary arterial hypertension drug cibotercept.

News

MSD adds rocket fuel to Winrevair's engine in PAH

ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch

NICE backs stomach cancer, PAH drugs for NHS use

United's PAH drug clears phase 3 trial, setting up filings

GSK grows pipeline with 35Pharma takeover, Frontier deal

Keros pulls study of Winrevair rival after safety signal

Safety fear halts Keros PAH trial dosing, hitting its shares

MSD adds rocket fuel to Winrevair's engine in PAH

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

pulmonary arterial hypertension

Editor's Picks